Optima Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Optima Capital’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-20	Closed	-$9.07K	–	1284
2025 Q4	$9.07K	Buy	+20	New	+$8.62K	﹤0.01%	537

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Optima Capital's VRTX Position: Q1 2026 in Review

Optima Capital sold out of Vertex Pharmaceuticals (VRTX) in Q1 2026, closing a stake of 20 shares — an estimated $9.07K sold.

Optima Capital first reported a position in VRTX in Q4 2025 and held it in 1 quarter. The position peaked at $9.07K in Q4 2025. 1,695 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Optima Capital reported no remaining Vertex Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Optima Capital sold 20 Vertex Pharmaceuticals shares in Q1 2026, an estimated $9.07K.
Optima Capital first reported a position in Vertex Pharmaceuticals in Q4 2025 and held it in 1 quarter.
Optima Capital's Vertex Pharmaceuticals position peaked at $9.07K in Q4 2025.
1,695 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Optima Capital's 13F filing for Q1 2026, filed 5 May 2026.